The camelina plant, a source of cooking oil for ce
Chennai 19th January 2021: Metrohm India Private L
Vibrio parahaemolyticus is a marine bacterium that
Neuried, Germany – 19 January 2021 –The rapid
Drug firm Strides Pharma Science on Friday said it
A microplate or microtiter plate (spelled Microtit
Roche, Basel, Switzerland, announced a partnership with Moderna Inc., Cambridge, Mass, to utilize the Elecsys Anti-SARS-CoV-2 S antibody test in Moderna’s mRNA-1273 vaccine research trials. This will facilitate the quantitative measurement of SARS-CoV-2 Compounds and help to establish a correlation between vaccine-induced protection and degrees of anti-receptor binding domain (RBD) antibodies. Significantly, Moderna’s vaccine triggers antibody response specifically to the RBD of the SARS-CoV-2 spike protein. This follows the recent announcement that Roche has received emergency use authorization (EUA) from the FDA for the Elecsys Anti-SARS-CoV-2 S antibody test.
“Roche values the collaboration with Moderna, which has already included the successful use of our qualitative Elecsys Anti-SARS-CoV-2 test, targeting the nucleocapsid protein, in an earlier part of the studies,” says Thomas Schinecker, CEO, Roche Diagnostics. “We are pleased to see that our quantitative Elecsys SARS-CoV-2 S test, which targets the spike protein, is now also being used as part of the Moderna vaccine trials, which could ultimately help to end this pandemic.”
Measuring the quantitative levels of anti-RBD SARS-CoV-2 antibodies using Roche’s test will help Moderna to gain valuable insights into the correlation between protection from vaccination and antibody levels. This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions.
This partnership with Moderna started by using the Elecsys Anti-SARS-CoV-2 test for qualitative determination of anti-N SARS-CoV-2 antibodies. This has been part of Moderna’s vaccine trials for baselining and assessing natural infection in trial participants.
For more information, visit www.roche.com.